Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab safety study with radiotherapy and temozolomide in primary glioblastoma
NL-OMON31960Active, not recruiting
- Sponsor
- Departments of Neurosurgery, Radiation Oncology, Clinical Oncology and Neurology Academisch Medisch Centrum Meibergdreef 15 1105 AZ Amsterdam +31 20 5669111
- Start
- Dec 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of bevacizumab and temozolomide in glioblastoma (GBM), sponsored by Departments of Neurosurgery, Radiation Oncology, Clinical Oncology and Neurology Academisch Medisch Centrum Meibergdreef 15 1105 AZ Amsterdam +31 20 5669111. Primary endpoint: Safety of combination treatment. Started Dec 2007; status: active, not recruiting.
02
Drugs
bevacizumabtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON31960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31960.